Sanofi: buys aficamten rights for China

(CercleFinance.com) - The US biopharmaceutical company Cytokinetics announced on Friday that France's Sanofi would acquire exclusive rights from Corxel to market aficamten, its experimental treatment for hypertrophic cardiomyopathy (HCM) in China.


In a press release, Cytokinetics recalls that it had development and distribution rights to the tablet from Corxel in 2020.

The drug project has since received Innovative Therapy status in China for symptomatic obstructive hypertrophic cardiomyopathy (oCMH), as well as a Priority Review in the country.

In a press release, Cytokinetics points out that it is still eligible to receive up to $150m depending on the progress of the project, as well as royalties of between 10% and 20% (not included) on sales of the drug.

The company is also due to receive an undisclosed amount in connection with the transaction concluded between Sanofi and Corxel.


Copyright (c) 2024 CercleFinance.com. All rights reserved.